# FDA Approves AvKARE's Generic Dapagliflozin AvKARE has received FDA approval for its generic dapagliflozin oral formulation, marking another entry into the competitive SGLT2 inhibitor market and potentially increasing price pressure on branded alternatives. The approval is expected to expand treatment accessibility for diabetes and heart failure patients while offering cost savings to payers and consumers.